Junshi Biosciences and Coherus Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
– Toripalimab plus chemotherapy demonstrates improvement in co-primary endpoints of PFS and OS in patients with advanced ESCC – – PFS and OS benefits were observed across all PD-L1 expression subgroups, including in patients with low PD-L1 expression – SHANGHAI, China and REDWOOD CITY, Calif., March 04, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd […]
Continue Reading